Ginkgo Bioworks/$DNA
1D1W1MYTD1Y5YMAX
Capital at risk
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
- Ticker
- $DNA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 485
- Headquarters
- Boston, United States
- Website
- www.ginkgo.bio
Ginkgo Bioworks Metrics
BasicAdvanced
$468M
-
-$4.96
1.79
-
Price and volume
Market cap
$468M
Beta
1.79
52-week high
$17.58
52-week low
$5.37
Average daily volume
1.2M
Financial strength
Current ratio
4.572
Quick ratio
4.333
Long term debt to equity
96.152
Total debt to equity
96.152
Profitability
EBITDA (TTM)
-271.598
Gross margin (TTM)
68.04%
Net profit margin (TTM)
-219.60%
Operating margin (TTM)
-224.33%
Effective tax rate (TTM)
0.19%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-17.27%
Return on equity (TTM)
-59.94%
Valuation
Price to revenue (TTM)
3.076
Price to book
1.03
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-2.33
Free cash flow yield (TTM)
-42.92%
Free cash flow per share (TTM)
-2.983
Growth
Revenue change (TTM)
-37.02%
Earnings per share change (TTM)
-15.30%
3-year revenue growth (CAGR)
-25.94%
3-year earnings per share growth (CAGR)
-43.08%
Bulls say / Bears say
Ginkgo launched the Ginkgo Cloud Lab, a web-based platform enabling researchers to remotely run experiments on its autonomous lab infrastructure, expanding its AI-driven contract research offerings. (Nasdaq)
Completed the divestiture of its Biosecurity business on April 3, 2026, allowing management to focus exclusively on higher-margin Cell Engineering and autonomous lab services to improve profitability. (SEC) (PR Newswire)
Maintains a strong liquidity position with $302 million in cash and marketable securities as of June 30, 2026, against a guided full-year cash burn of $125–150 million, providing runway into 2028. (TradingView) (EarningsCalls)
Q2 2026 revenue plunged 48% year-over-year to $20 million from $39 million, signaling significant demand weakness following program rationalization and the Biosecurity divestiture. (Yahoo Finance) (TradingView)
Despite cost-cutting efforts, Ginkgo reported a GAAP net loss of $57.3 million and an Adjusted EBITDA loss of $36.3 million in Q2 2026, underscoring that profitability remains distant. (TradingView) (Yahoo Finance)
Shares have slumped over 80% in the past 12 months and fell a further 4% after management issued a downbeat full-year 2025 forecast, reflecting deep investor skepticism. (TradingView)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
Ginkgo Bioworks News
AllArticlesVideos
Funds containing Ginkgo Bioworks
AllEURUSDGBP
Fund name | Fund size | $DNA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.